Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
Holding COLL?
Track your performance easily
COLL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.95 - $40.95
Previous Close$38.78
Volume79.17K
Average Volume (3M)435.63K
Market Cap
$1.25B
Enterprise Value$1.54B
Total Cash (Recent Filing)$271.63M
Total Debt (Recent Filing)$559.46M
Price to Earnings (P/E)15.0
Beta0.53
Next Earnings
Nov 06, 2024EPS Estimate
$1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.58
Shares Outstanding32,213,751
10 Day Avg. Volume255,051
30 Day Avg. Volume435,627
Standard Deviation0.15
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.77
Price to Sales (P/S)2.09
Price to Cash Flow (P/CF)4.50
P/FCF Ratio4.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit4.71
Enterprise Value/Ebitda5.91
Forecast
1Y Price Target
$43.50Price Target Upside12.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Announces Major Acquisition and Financing Deal
PremiumCompany Announcements
Collegium Pharmaceutical Releases Earnings InsightsBulls Say, Bears Say
Bulls Say
AcquisitionThe Ironshore deal diversifies the business from just pain and increases the growth and margin profile of the company.
Business StrategyThe company is generating significant cash flow and deploying capital in a shareholder-friendly way through repurchases and debt paydown.
Financial PerformanceThe new full-year 2024 revenue guidance is raised to $620-635M, indicating a significant upside.
Bears Say
Analyst RatingThe company maintains a Hold rating, and awaits more details on accretion parameters.
Sales PerformanceLower than expected sales in both Xtampza and the Nucynta franchise.
Share Price PressureShares are under pressure (down 7%-8%) most likely due to the purchase cost (5.25x sales) of the asset, and the limited details the co. was able to provide regarding additional spend and accretion.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $20.95 and its highest was $40.95 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Currently, no data Available
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Aug 08, 2024. The company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.485 by $0.135.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is $1.61.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,213,753 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.62 in its last earnings report, beating expectations of $1.485. Following the earnings report the stock price went up 0.51%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Among the largest hedge funds holding Collegium Pharmaceutical’s share is Royce & Associates LLC. It holds Collegium Pharmaceutical’s shares valued at 10M.
---
Collegium Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.50 (12.03% Upside)
$43.50 (12.03% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 144.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.51%
12-Months-Change
Fundamentals
Return on Equity
47.87%
Trailing 12-Months
Asset Growth
-13.22%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q2 2024
0:00 / 0:00
---
COLL Stock 12 Month Forecast
Average Price Target
$43.50
▲(12.03% Upside)
Technical Analysis
Best Analysts Covering COLL
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+1.88%
reiterated a buy rating 16 days ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +1.88% per trade.
---